

Reference List

Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM. Established and Novel Prognostic Biomarkers in Multiple Myeloma. *Am Soc Clin Oncol Educ Book*.2017;37(37):548-560. doi:10.14694/EDBK_175175
[10.1200/EDBK_175175](https://doi.org/10.1200/EDBK_175175)

De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P. An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. *Expert Rev Mol Diagn*.2019;19(3):249-258. doi:10.1080/14737159.2019.1583103

Jew S, Chang T, Bujarski S, et al. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. *Br J Haematol*.2021;192(2):272-280. doi:10.1111/bjh.16752

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Understanding Prognostic versus Predictive Biomarkers. 2016 Dec 22. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK402284/> Co-published by National Institutes of Health (US), Bethesda (MD).

Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. *Haematologica*.2017;102(4):785-795. doi:10.3324/haematol.2016.150896

Girgis S, Wang Lin SX, Pillarisetti K, et al. Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma. *J Clin Oncol*. 2021;39(15_suppl):8047. doi:10.1200/JCO.2021.39.15_suppl.8047

Gupta N, Sharma A, Sharma A. Emerging biomarkers in Multiple Myeloma: A review. *Clin Chim Acta*.2020;503:45-53. doi:10.1016/j.cca.2019.12.026

Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*.2016;17(8):e328-e346. doi:10.1016/S1473-2045(16)30206-6

Lesokhin AM, Levy MY, Dalvisio AP, et al. Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*. 2020;136(Supplement 1):8-9. doi:10.1182/blood-2020-133355

Reference List

NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma Version 4.2022. Updated December 15, 2021. Accessed January 15, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.

Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. *Blood*.2019;133(7):660-675. [doi:10.1182/blood-2018-09-825331](https://doi.org/10.1182/blood-2018-09-825331)

Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. *CPT Pharmacometrics Syst Pharmacol*.2021;10(8):851-863. [doi:10.1002/psp4.12660](https://doi.org/10.1002/psp4.12660)

Soliman AM, Das S, Teoh SL. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. *Int J Mol Sci*.2021;22(14) [doi:10.3390/ijms22147470](https://doi.org/10.3390/ijms22147470)

van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. *Blood Cancer Discov*.2021;2(4):302-318. [doi:10.1158/2643-3230.bcd-20-0227](https://doi.org/10.1158/2643-3230.bcd-20-0227)

Visram A, Soof C, Rajkumar SV, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. *Blood Cancer J*.2021;11(6):120. [doi:10.1038/s41408-021-00505-4](https://doi.org/10.1038/s41408-021-00505-4)